CARDIOPROGRESS
Foundation for the advancement of cardiology

Dapagliflozin Gets Expanded Heart Failure Indication in Europe The European Commission (EC) has expanded the indication for dapagliflozin (Forxiga) to include heart failure (HF) across the full spectrum of left ventricular ejection fraction — including HF with mildly reduced and preserved ejection fraction, AstraZeneca has announced.

Cath Ablation for AF No Less Safe, Effective in Cancer Patients Catheter ablation for atrial fibrillation (AF) is effective and safe in patients with a history of cancer and those receiving cardiotoxic therapies. The ablation success rate in patients with cancer was similar to that observed in patients without cancer.

It’s not just what we eat, but why we eat that’s important for heart health The study found that emotional eating was associated with cardiovascular problems, and that stress contributed to this relationship.

Very Hot, Very Cold Days Tied to Higher CVD Mortality Extremely hot and extremely cold temperatures were associated with a greater risk of cardiovascular mortality in an analysis of data from countries around the world.

Mortality After Acute Stroke Worsened by Accompanying Acute AF Acute atrial fibrillation (AF) is an independent predictor of severity of neurological deficits from early acute ischemic stroke and a high-probability predictor of death within 30 days after such strokes.

24% of Adults With Hypertension Have Subclinical Hypothyroidism The prevalence of subclinical hypothyroidism (SCH) was high, 24%, among people with hypertension in Gansu Province, China. The prevalence was 17% prevalence among normotensive adults from the same region.

Tirzepatide Cuts BP During Obesity Treatment CHICAGO — Treatment with the "twincretin" tirzepatide led to significant and potentially clinically meaningful cuts in 24-hour ambulatory blood pressure, compared with placebo, while causing modest increases in heart rate, in a prespecified substudy of the SURMOUNT-1 trial.

Preeclampsia Linked to Increased Risk for Heart Disease, Stroke in Offspring Preeclampsia is a major cause of maternal and perinatal morbidity and mortality, affecting as many as 5% of pregnancies worldwide. New evidence suggests that the complication doesn't end with delivery.

Four-Drug Combo Gets BP Down in One Step: QUARTET-USA Use of a combination antihypertensive product containing quarter doses of four different drugs could be an effective strategy to get patients to target blood pressures in one step, a new study suggests.

AI eye checks can predict heart disease risk in less than minute, finds study Breakthrough opens door to a highly effective, non-invasive test that does not need to be done in a clinic. An artificial intelligence tool that scans eyes can accurately predict a person’s risk of heart disease in less than a minute, researchers say.

Dedicated to eternal memory Dear colleagues!
On these holidays, the Cardioprogress Foundation remembers the heroes of the Great Patriotic War, whose feat was immortalized in the hearts of their descendants.

Spanish Cardiologists Release Gender-Specific CV Guide The Spanish Society of Cardiology (SEC) Working Group on Women and Cardiovascular Diseases (SEC-GT CVD in Women) and the Association of Preventive Cardiology have convened an interdisciplinary group of experts from various Spanish societies and associations issued SEC-approved clinical guidelines published in the English-language edition of the Revista Española de Cardiología journal, which is designed to help medical professionals. in the diagnosis and treatment of cardiovascular diseases in women, paying special attention to gender differences.

Dear colleagues! I welcome you on behalf of the Organizing Committee of the XI International Forum for Cardiology and Internal Medicine, which will be held from March 22 to 24, 2022 in Moscow.

Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.

The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine Dear Colleagues! We invite you to take part in XI International Forum of Cardiology and Internal Medicine. Forum will take place on 22-24 March 2022 in Moscow (online).

Analysis of the activities of the "Cardioprogress" foundation: results of 2021 Dear colleagues! In 2021, a number of significant events took place in cardiology. Due to the continuation of restrictive measures, most scientific events were organized online. This required adaptation and the acquisition of new skills. However, all planned events took place.

Aspirin is linked with increased risk of heart failure Aspirin use is associated with a 26% raised risk of heart failure in people with at least one predisposing factor for the condition. That’s the finding of a study published today in ESC Heart Failure, a journal of the European Society of Cardiology (ESC).

Depression worsened during pandemic, boosting heart disease risk, experts warn It may translate into another long-term effect of the coronavirus crisis — more heart disease cases even in people who never had COVID-19 at all. More than one-third of patients studied reported becoming depressed or experiencing continued symptoms of depression during the first year of the pandemic.

Longer Sleep Improves Cardiovascular Outcomes: Time to Make Sleep a Priority Causal diagrams demonstrating potential relationships between genetic causes (G) of sleep duration, sleep duration (S), and a cardiovascular outcome (Y). (A) G is a valid instrumental variable for the relationship of S and Y, and can be used to estimated the S–Y association (orange arrow). (B) G has a pleiotropic association with Y. Because there are no unmeasured confounders (U) of the S–Y association, causal mediation analysis can be used to estimate both the direct (pleiotropic) association of G and Y, and the indirect effect via S. (C) The pleiotropic effect of G on Y can be measured by blocking the pathway through S, which is done by conditioning on levels of S. (D) The effect of S on Y independently of G can be measured by blocking pathways through G and C (measured confounders) by conditioning or using matching methods.